Structure of neurotropic adeno-associated virus AAVrh.8
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus rhesus isolate 8 (AAVrh.8) is a leading vector for the treatment of neurological diseases due to its efficient transduction of neuronal cells and reduced peripheral tissue tropism. Toward identification of the capsid determinants for these properties, the structure of AAVrh.8 was determined by X-ray crystallography to 3.5 Å resolution and compared to those of other AAV isolates. The capsid viral protein (VP) structure consists of an αA helix and an eight-stranded anti-parallel β-barrel core conserved in parvoviruses, and large insertion loop regions between the β-strands form the capsid surface topology. The AAVrh.8 capsid exhibits the surface topology conserved in all AAVs: depressions at the icosahedral twofold axis and surrounding the cylindrical channel at the fivefold axis, and three protrusions around the threefold axis. A structural comparison to serotypes AAV2, AAV8, and AAV9, to which AAVrh.8 shares ~84, ~91, and ~87% VP sequence identity, respectively, revealed differences in the surface loops known to affect receptor binding, transduction efficiency, and antigenicity. Consistent with this observation, biochemical assays showed that AAVrh.8 is unable to bind heparin and does not cross-react with conformational monoclonal antibodies directed against the other AAVs compared. This structure of AAVrh.8 thus identified capsid surface differences which can serve as template regions for rational design of vectors with enhanced transduction for specific tissues and escape pre-existing antibody recognition. These features are essential for the creation of an AAV vector toolkit that is amenable to personalized disease treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 1×
“…muscular dystrophy, hemophilia B, cystic fibrosis, Alzheimer’s disease, arthritis, lipoprotein lipase deficiency, Parkinson’s disease, and HIV infection (e.g. (Carter, 2006; Coura Rdos and Nardi, 2007; Daya and Berns, 2008; Mueller and Flotte, 2008; Nathwani et al., 2011; Stieger et al., 2011)).”
BackgroundIntravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 8×
“D) from ideal bond lengths and angles were obtained from the CNS program (Brunger et al., 1998) and the average Bfactor for the VP3 model, solvent molecules, NT, and ions were calculated using the MOLEMAN program (Kleywegt and Jones, 1997).”
BackgroundInfluentialClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Self-citationBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926 · cited 1×
“…muscular dystrophy, hemophilia B, cystic fibrosis, Alzheimer’s disease, arthritis, lipoprotein lipase deficiency, Parkinson’s disease, and HIV infection (e.g. (Carter, 2006; Coura Rdos and Nardi, 2007; Daya and Berns, 2008; Mueller and Flotte, 2008; Nathwani et al., 2011; Stieger et al., 2011)).”
BackgroundTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893 · cited 1×
“…non-pathogenic parvovirus adeno-associated virus (AAV) show great promise as gene delivery vectors due to their ability to deliver packaged foreign genes for stable and long-term protein expression in a wide range of human tissues (reviewed in (Flotte and Carter, 1995; Mingozzi and High, 2011)).”
BackgroundThe atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558 · cited 4×
“AAV2 Y704 is also part of a series of tyrosines which when mutated to phenylalanines resulted in improved intracellular trafficking to the nucleus and hence increase in transduction efficiency dependent on the cell line (Zhong et al., 2008).”
BackgroundInfluentialSelf-citationDirected evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538 · cited 3×
“…Heparan sulfate receptor binding/Transduction (Kern et al., 2003; Opie et al., 2003; Summerford and Samulski, 1998); polyclonal neutralization (Maheshri et al., 2006); C37-B neutralization (Girod et al., 1999; Gurda et al., 2013; Huttner et al., 2003; Wobus et al., 2000); D3 neutralization…”
BackgroundGenetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. (1999) · Nature Medicine · doi:10.1038/12491 · Cited by 405
Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400
Self-citationIdentification of a heparin-binding motif on adeno-associated virus type 2 capsids
Kern, A., Schmidt, K., Leder, C., Müller, O. J., Wobus, C. E., Bettinger, K., Von der Lieth, C. W., King, J. A., & Kleinschmidt, J. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.11072-11081.2003 · Cited by 380
Zhang, H., Yang, B., Mu, X., Ahmed, S. S., Su, Q., He, R., Wang, H., Mueller, C., Sena-Esteves, M., Brown, R., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.98 · Cited by 291 · cited 8×
“D) from ideal bond lengths and angles were obtained from the CNS program (Brunger et al., 1998) and the average Bfactor for the VP3 model, solvent molecules, NT, and ions were calculated using the MOLEMAN program (Kleywegt and Jones, 1997).”
BackgroundInfluentialWobus, C. E., Hügle-Dörr, B., Girod, A., Petersen, G., Hallek, M., & Kleinschmidt, J. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9281-9293.2000 · Cited by 273 · cited 30×
“Mutagenesis studies have identified residues N498, W503, and P504, and Q590 in VR-V and VR-VIII, respectively, to affect liver and muscle-specific transduction in AAV9 (Pulicherla et al., 2011) and all these residues except P504 are conserved in AAVrh.8, AAV8, and AAV2 (T504 in AAVrh.8; T506 in AAV8 and T503 in AAV2).”
BackgroundMethodInfluentialLi, W., Asokan, A., Wu, Z., Van Dyke, T., DiPrimio, N., Johnson, J. S., Govindaswamy, L., Agbandje-McKenna, M., Leichtle, S., Eugene Redmond Jr, D., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.100 · Cited by 261
Self-citationMoskalenko, M., Chen, L., van Roey, M., Donahue, B. A., Snyder, R. O., McArthur, J. G., & Patel, S. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.1761-1766.2000 · Cited by 253 · cited 3×
“…Wobus et al., 2000) Galactose receptor binding/transduction (Bell et al., 2012) II Transduction (Lochrie et al., 2006); polyclonal neutralization (Moskalenko et al., 2000); role in genome packaging (Bleker et al., 2005; Sonntag et al., 2006) III Transduction (Lochrie et al., 2006; Wu et al.,…”
BackgroundInfluentialStructural insight into the unique properties of adeno-associated virus serotype 9
DiMattia, M. A., Nam, H.-J., Van Vliet, K., Mitchell, M., Bennett, A., Gurda, B. L., McKenna, R., Olson, N. H., Sinkovits, R. S., Potter, M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.07232-11 · Cited by 219 · cited 3×
“…AAVrh.8 VP3 crystal structure was superposed onto the VP3 structures of AAV2, AAV8, and AAV9 (PDB accession no. 1lp3, 2qa0, and 3ux1, respectively) (DiMattia et al., 2012; Nam et al., 2007; Xie et al., 2002) using the secondary structure matching (SSM) program available in PDBefold (Krissinel and…”
BackgroundMethodSelf-citationFunctional implications of the structure of the murine parvovirus, minute virus of mice
Agbandje-McKenna, M., Llamas-Saiz, A. L., Wang, F., Tattersall, P., & Rossmann, M. G. (1998) · Structure · doi:10.1016/s0969-2126(98)00137-3 · Cited by 218 · cited 3×
“33) and the autonomous parvoviruses (minute virus of mice and canine parvovirus) (Agbandje-McKenna et al., 1998; DiMattia et al., 2012; Mikals et al., 2014; Nam et al., 2007; Xie and Chapman, 1996).”
BackgroundSelf-citationAAV Capsid Structure and Cell Interactions
Agbandje-McKenna, M., & Kleinschmidt, J. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_3 · Cited by 215
Self-citationYang, B., Li, S., Wang, H., Guo, Y., Gessler, D. J., Cao, C., Su, Q., Kramer, J., Zhong, L., Ahmed, S. S., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.68 · Cited by 213 · cited 10×
“D) from ideal bond lengths and angles were obtained from the CNS program (Brunger et al., 1998) and the average Bfactor for the VP3 model, solvent molecules, NT, and ions were calculated using the MOLEMAN program (Kleywegt and Jones, 1997).”
BackgroundInfluentialStructurally mapping the diverse phenotype of adeno-associated virus serotype 4
Govindasamy, L., Padron, E., McKenna, R., Muzyczka, N., Kaludov, N., Chiorini, J. A., & Agbandje-McKenna, M. (2006) · Journal of Virology · doi:10.1128/jvi.01536-06 · Cited by 205 · cited 16×
“A NT has been observed in the same location for AAV1, AAV3b, AAV4, AAV6, AAV8, and AAVrh32.”
BackgroundMethodInfluentialSelf-citationLochrie, M. A., Tatsuno, G. P., Christie, B., McDonnell, J. W., Zhou, S., Surosky, R., Pierce, G. F., & Colosi, P. (2006) · Journal of Virology · doi:10.1128/jvi.80.2.821-834.2006 · Cited by 201 · cited 16×
“Mutagenesis, biochemical, and structural studies demonstrate that residues in these VRs play important functional roles, including receptor attachment, transduction determination, and immunogenic reactivity (reviewed in (Adachi et al., 2014; Gurda et al., 2012; Gurda et al., 2013; Kotchey et al., 2011; Li et al., 2008…”
BackgroundMethodInfluentialBleker, S., Sonntag, F., & Kleinschmidt, J. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.4.2528-2540.2005 · Cited by 200 · cited 2×
“…(Bell et al., 2012) II Transduction (Lochrie et al., 2006); polyclonal neutralization (Moskalenko et al., 2000); role in genome packaging (Bleker et al., 2005; Sonntag et al., 2006) III Transduction (Lochrie et al., 2006; Wu et al., 2000); A20 neutralization (Girod et al., 1999; Lochrie…”
BackgroundResultKronenberg, S., Böttcher, B., von der Lieth, C. W., Bleker, S., & Kleinschmidt, J. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.9.5296-5303.2005 · Cited by 198 · cited 1×
“Combined with biochemical data, this observation supports the speculation that the phospholipase A2 domain within VP1u and VP1/VP2 nuclear localization signals are externalized through the fivefold channel (Bleker et al., 2005; Grieger et al., 2006; Kronenberg et al., 2005; Sonntag et al., 2006).”
ResultSonntag, F., Köther, K., Schmidt, K., Weghofer, M., Raupp, C., Nieto, K., Kuck, A., Gerlach, B., Böttcher, B., Müller, O. J., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05359-11 · Cited by 184 · cited 9×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript Table 4 Known function(s) of AAV variable regions VR AAV2 AAV8 AAV9 I Transduction (Bowles et al., 2012); A20 neutralization (Girod et al., 1999; Lochrie et al., 2006; McCraw et al., 2012; Wobus et al., 2000); D3 neutralization (Girod et a…”
BackgroundMethodInfluentialAsokan, A., Hamra, J. B., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.00843-06 · Cited by 183
Self-citationDNA Shuffling of Adeno-associated Virus Yields Functionally Diverse Viral Progeny
Koerber, J. T., Jang, J.-H., & Schaffer, D. V. (2008) · Molecular Therapy · doi:10.1038/mt.2008.167 · Cited by 181 · cited 1×
“…et al., 2012; Li et al., 2008; Salganik et al., 2014); A20 neutralization (Lochrie et al., 2006; McCraw et al., 2012); IVIG neutralization (Koerber et al., 2008); polyclonal neutralization (Maheshri et al., 2006; Moskalenko et al., 2000); Second-strand synthesis and transcription…”
BackgroundWang, L., Calcedo, R., Nichols, T. C., Bellinger, D. A., Dillow, A., Verma, I. M., & Wilson, J. M. (2005) · Blood · doi:10.1182/blood-2004-10-3867 · Cited by 173 · cited 1×
“TBG.GFP.BGH, was manufactured by PennVector at the University of Pennsylvania (Philadelphia, PA) as previously described (Wang et al., 2005).”
MethodSelf-citationGrieger, J. C., Snowdy, S., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.02723-05 · Cited by 172 · cited 1×
“Combined with biochemical data, this observation supports the speculation that the phospholipase A2 domain within VP1u and VP1/VP2 nuclear localization signals are externalized through the fivefold channel (Bleker et al., 2005; Grieger et al., 2006; Kronenberg et al., 2005; Sonntag et al., 2006).”
ResultSnijder, J., van de Waterbeemd, M., Damoc, E., Denisov, E., Grinfeld, D., Bennett, A., Agbandje-McKenna, M., Makarov, A., & Heck, A. J. R. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502616y · Cited by 168 · cited 4×
“…from 60 copies (in total) of three viral proteins (VPs), VP1 (~87 kDa), VP2 (~73 kDa), and VP3 (~61 kDa) encoded from the cap gene and stochastically incorporated in an estimated ratio of 1:1:10, respectively (Buller and Rose, 1978; Johnson et al., 1971; Rose et al., 1971; Snijder et al., 2014).”
InfluentialSelf-citationElectron cryo‐microscopy and image reconstruction of adeno‐associated virus type 2 empty capsids
Kronenberg, S., Kleinschmidt, J. A., & Böttcher, B. (2001) · The EMBO Reports · doi:10.1093/embo-reports/kve234 · Cited by 161 · cited 2×
“…cryoelectron microscopy and image reconstruction (cryo-reconstruction) (DiMattia et al., 2012; Govindasamy et al., 2006; Govindasamy et al., 2013; Kronenberg et al., 2001; Lerch et al., 2010; Mikals et al., 2014; Nam et al., 2007; Ng et al., 2010; Padron et al., 2005; Walters et al., 2004; Xie…”
BackgroundMethodCombinatorial engineering of a gene therapy vector: directed evolution of adeno‐associated virus
Perabo, L., Endell, J., King, S., Lux, K., Goldnau, D., Hallek, M., & Büning, H. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.849 · Cited by 136 · cited 2×
“…(Kern et al., 2003; Opie et al., 2003; Summerford and Samulski, 1998); polyclonal neutralization (Maersch et al., 2010; Moskalenko et al., 2000; Perabo et al., 2006) Transduction (Gurda et al., 2012; Raupp et al., 2012) Galactose receptor binding/transduction (Bell et al., 2012); liver…”
BackgroundCanine Parvovirus Capsid Structure, Analyzed at 2.9 Å Resolution
Xie, Q., & Chapman, M. S. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0657 · Cited by 134
Capsid antibodies to different adeno-associated virus serotypes bind common regions
Gurda, B. L., DiMattia, M. A., Miller, E. B., Bennett, A., McKenna, R., Weichert, W. S., Nelson, C. D., Chen, W.-J., Muzyczka, N., Olson, N. H., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00622-13 · Cited by 127 · cited 13×
“Mutagenesis studies have identified residues N498, W503, and P504, and Q590 in VR-V and VR-VIII, respectively, to affect liver and muscle-specific transduction in AAV9 (Pulicherla et al., 2011) and all these residues except P504 are conserved in AAVrh.8, AAV8, and AAV2 (T504 in AAVrh.8; T506 in AAV8 and T503 in AAV2).”
BackgroundMethodInfluentialSelf-citationHuttner, N. A., Girod, A., Perabo, L., Edbauer, D., Kleinschmidt, J. A., Büning, H., & Hallek, M. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302123 · Cited by 124
Structure of Adeno-Associated Virus Serotype 5
Walters, R. W., Agbandje-McKenna, M., Bowman, V. D., Moninger, T. O., Olson, N. H., Seiler, M., Chiorini, J. A., Baker, T. S., & Zabner, J. (2004) · Journal of Virology · doi:10.1128/jvi.78.7.3361-3371.2004 · Cited by 114
Self-citationCharacterization of adenovirus-associated virus-induced polypeptides in KB cells
Buller, R. M., & Rose, J. A. (1978) · Journal of Virology · doi:10.1128/jvi.25.1.331-338.1978 · Cited by 111 · cited 1×
“…from 60 copies (in total) of three viral proteins (VPs), VP1 (~87 kDa), VP2 (~73 kDa), and VP3 (~61 kDa) encoded from the cap gene and stochastically incorporated in an estimated ratio of 1:1:10, respectively (Buller and Rose, 1978; Johnson et al., 1971; Rose et al., 1971; Snijder et al., 2014).”
BackgroundNam, H.-J., Gurda, B. L., McKenna, R., Potter, M., Byrne, B., Salganik, M., Muzyczka, N., & Agbandje-McKenna, M. (2011) · Journal of Virology · doi:10.1128/jvi.05305-11 · Cited by 108 · cited 5×
“Interestingly, AAV8 Y707 and adjacent residues are involved in pH-mediated structural transitions predicted to occur during virus trafficking through the endocytic pathway (Nam et al., 2011), and E563A and H526A mutations in AAV2 (equivalent to E564 and H527 in AAVrh.”
BackgroundMethodInfluentialSelf-citationStructural insights into adeno-associated virus serotype 5
Govindasamy, L., DiMattia, M. A., Gurda, B. L., Halder, S., McKenna, R., Chiorini, J. A., Muzyczka, N., Zolotukhin, S., & Agbandje-McKenna, M. (2013) · Journal of Virology · doi:10.1128/jvi.00867-13 · Cited by 95
Self-citationStructure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20
McCraw, D. M., O’Donnell, J. K., Taylor, K. A., Stagg, S. M., & Chapman, M. S. (2012) · Virology · doi:10.1016/j.virol.2012.05.004 · Cited by 84
Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes
Maersch, S., Huber, A., Büning, H., Hallek, M., & Perabo, L. (2010) · Virology · doi:10.1016/j.virol.2009.10.021 · Cited by 50
Transduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injection
Giove, T. J., Sena-Esteves, M., & Eldred, W. D. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.08.011 · Cited by 27 · cited 2×
“Recent preclinical studies with AAVrh.8 have demonstrated that it efficiently transduces the retina, and crosses the bloodbrain barrier (BBB) to transduce neuronal cells while also displaying reduced tropism for peripheral tissues (Giove et al., 2010; Yang et al., 2014).”
Background
Cited by
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
Manufacturing challenges and rational formulation development for AAV viral vectors
Srivastava, A., Mallela, K. M. G., Deorkar, N., & Brophy, G. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.03.024 · Cited by 269
Capsid modifications for targeting and improving the efficacy of AAV vectors
Büning, H., & Srivastava, A. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.008 · Cited by 260
Twenty-Five Years of Structural Parvovirology
Mietzsch, M., Pénzes, J. J., & Agbandje-McKenna, M. (2019) · Viruses · doi:10.3390/v11040362 · Cited by 197
“To circumvent these inhibitory events, different strategies have been developed, including the utilization of immunosuppressants [130–133], the utilization of alternative natural AAV capsids that are not detected by the pre-existing human antibodies [68], the use of empty capsids as decoys [134], and the structure-gui…”
BackgroundMethodInfluentialSelf-citationUniversal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes
Nass, S. A., Mattingly, M. A., Woodcock, D. A., Burnham, B. L., Ardinger, J. A., Osmond, S. E., Frederick, A. M., Scaria, A., Cheng, S. H., & O’Riordan, C. R. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.12.004 · Cited by 146
Metadata
- Authors
- Halder, S., Van Vliet, K., Smith, J. K., Duong, T. T. P., McKenna, R., Wilson, J. M., & Agbandje-McKenna, M.
- Venue
- Journal of Structural Biology
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 192
- Issue
- 1
- Pages
- 21-36
- ISSN
- 1047-8477 (ISSN-L)
- OpenAlex
- W1507799217
- Cited by
- 64
- References
- 42
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.